Table 4. Phase III ongoing trials in adjuvant renal cell cancer.

Study name	Histology	Risk/stage	Trial design
ASSURE80	All	pT1b G3–4, pT2–4, N+	Sorafenib vs sunitinib vs placebo
SORCE81	All	High and intermediate risk	1-year sorafenib vs 3-year sorafenib vs placebo
S-TRAC82	Predominant clear cell	High risk (UISS criteria)	Sunitinib vs placebo
ARISER83–86	Clear cell	T1b or T2, N0/NX, M0, each with G≥3, or T3a/b/c, or T4 N0/NX, M0, or any T stage and N+M0	Monoclonal chimeric antibody cG250 vs placebo
EVEREST87,88	All	Intermediate high risk or very high risk	Everolimus vs placebo
PROTECT89,90	Clear-cell or predominant clear-cell	pT2, G3 or G4, N0; or pT3, G any, N0; or pT4, G any, N0; or pT any, G any, N1	Pazopanib vs placebo

UISS, University of California Los Angeles Integrated Staging System.